Together, results from the in vivo studies in Figure 6A‐C confirmed our in vitro studies and demonstrated that GPER could promote NSCLC progression by the modulation of YAP1‐TEAD/QKI/circNOTCH1/m6A methylated NOTCH1 signalling (Figure 6D). The gene discussed is YAP1; the disease is non-small cell lung carcinoma.